ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2407

Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis

Shozo Ohtsuki1, Chenyao Wang2, Ryu Watanabe3, Hui Zhang3, Mitsuhiro Akiyama3, Kenneth Warrington4, Gerald J. Berry3, Jorg Goronzy4 and Cornelia M. Weyand5, 1Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN, 2Mayo Clinic College of Medicine and Science, Rochester, MN, 3Stanford University School of Medicine, Stanford, CA, 4Mayo Clinic, Rochester, MN, 5Mayo Clinic School of Medicine and Stanford University, Rochester, MN

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, giant cell arteritis, innate immunity, macrophages, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a medium and large vessel vasculitis with pathognomonic granulomatous infiltrates in the vessel wall. During the early stages of vasculitis, the bone marrow accelerates myelopoiesis, providing critical effector cells that control T cell immunity via antigen-presenting function. GCA macrophages are distinguished from healthy cells by the low expression of the checkpoint molecules PD-L1 and CD155. Here, we have defined macrophage profiles of co-stimulatory and co-inhibitory ligands and have tested the functional implications of co-stimulation/co-inhibition on T cell differentiation.

Methods: Monocytes from the peripheral blood of GCA patients and age-matched controls were differentiated into monocyte-derived macrophages (MDM) with M-CSF and polarized with LPS/IFN-γ. Patients with granulomatosis with polyangiitis (GPA) served as disease controls. Ligand expression was measured by flow cytometry or by immunofluorescence staining in granulomatous tissue lesions. Cellular protein expression was analyzed by immunoblotting and immunoprecipitation.

Results: Compared to age-matched controls and GPA patients, MDM from GCA patients were strongly positive for CD80/CD86 but expressed low levels of PD-L1 (p=0.0035) and CD155 (p=0.0005). Healthy MDM were consistently double positive for PD-L1 and CD155, but GCA patients had a population of PD-L1low CD155low and of PD-L1neg CD155low MDM. Combined PD-L1/CD155 low expression was maintained in tissue macrophages in inflamed arteries. PD-L1 and CD155 mRNA transcripts were equally abundant in patients and controls and immunoblotting demonstrated similar amounts of total CD155 protein in GCA and control MDM. Subcellular mapping studies with organelle specific markers placed CD155 into the endoplasmic reticulum in GCA MDM and immunoprecipitation experiments confirmed that CD155 protein was retained by ER membranes (p=0.004 GCA vs. control). Transcriptomic studies identified an ER stress signature in GCA MDM, and tunicamycin-induced ER stress was sufficient to cause CD155 retention in healthy MDM (p=0.008). We explored whether the low surface expression of PD-L1 and CD155 had functional consequences. CD155low MDM shifted the differentiation of interacting CD4+ T cells, favoring the expansion of poorly differentiated multifunctional memory T cells.Anti-CD155 blocking antibodies produced a similar bias in T cell differentiation (p< 0.001). Defective expression of the inhibitory ligands was resistant to immunosuppressive therapy and persisted in steroid treated patients.

Conclusion: Patients with GCA generate abnormal antigen-presenting cells that are characterized by the lack of inhibitory ligands. The defect is shared by at least two checkpoints, involving PD-L1- and CD155-dependent signaling. Underlying molecular defects map to the endoplasmic reticulum, which traps PD-L1 and CD155 in the cytosol and prevents surface translocation. PD-L1low CD155low macrophages function as immuno-permissive antigen-presenting cells, supporting the unopposed expansion of multifunctional, pro-inflammatory effector T cells.


Disclosures: S. Ohtsuki: None; C. Wang: None; R. Watanabe: None; H. Zhang: None; M. Akiyama: None; K. Warrington: Bristol-Myers Squibb(BMS), 5, Chemocentryx, 1, 6, Eli Lilly, 5, kiniksa, 5; G. Berry: None; J. Goronzy: AbbVie/Abbott, 1, Bristol-Myers Squibb(BMS), 1, Gilead, 1; C. Weyand: AbbVie/Abbott, 1, Bristol-Myers Squibb(BMS), 1, Gilead, 1.

To cite this abstract in AMA style:

Ohtsuki S, Wang C, Watanabe R, Zhang H, Akiyama M, Warrington K, Berry G, Goronzy J, Weyand C. Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/immuno-permissive-antigen-presenting-cells-in-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immuno-permissive-antigen-presenting-cells-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology